Curium International

{
  "events": [
    {
      "kind": "director_in",
      "role": "commissaire",
      "person": {
        "rrn": null,
        "name": "Callens Vandelanotte NV",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "repr\u00E9sentant permanent du commissaire",
      "person": {
        "rrn": null,
        "name": "Erik Snauwaert",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "CURIUM INTERNATIONAL"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "CURIUM INTERNATIONAL"
  },
  "legal_form_change": {
    "new": "Soci\u00E9t\u00E9 anonyme",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "stage": "proposal",
  "notary": {
    "name": "Xavier Defourt",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-05-24",
    "filing_date": "2024-05-15",
    "act_kind_objet": "Projet d\u0027op\u00E9ration assimil\u00E9e \u00E0 une fusion par absorption au sens des"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2024-04-18",
    "unanimous": true
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0860.215.596",
        "name": "CURIUM INTERNATIONAL",
        "role": "acquiring",
        "address": "BOULEVARD BISCHOFFSHEIM 39 (BT\u00C9 4), 1000 BRUXELLES",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0874.830.726",
        "name": "IBA PHARMA INVESTMENTS",
        "role": "absorbed",
        "address": "BOULEVARD BISCHOFFSHEIM 39 (BTE 4), 1000 BRUXELLES",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "12:7",
      "12:50",
      "12:24"
    ],
    "is_cross_border": false,
    "is_silent_merger": true,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "L\u0027op\u00E9ration consiste en le transfert int\u00E9gral du patrimoine (actif et passif) de IBA PHARMA INVESTMENTS \u00E0 son actionnaire unique, CURIUM INTERNATIONAL, par dissolution sans liquidation.",
    "equity_transferred_eur": null,
    "accounting_effective_date": "2024-01-01"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "CURIUM INTERNATIONAL",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "Thales",
    "person_name": null,
    "org_rep_person_name": "Emmanuel Georgas"
  },
  "summary_narrative": "CURIUM INTERNATIONAL SA et IBA PHARMA INVESTMENTS SA ont convenu d\u0027une op\u00E9ration assimil\u00E9e \u00E0 une fusion par absorption, conform\u00E9ment aux articles 12:7 et 12:50 du Code des soci\u00E9t\u00E9s et des associations. La soci\u00E9t\u00E9 absorb\u00E9e, IBA PHARMA INVESTMENTS, sera dissoute sans liquidation, et son patrimoine int\u00E9gral sera transf\u00E9r\u00E9 \u00E0 son actionnaire unique, CURIUM INTERNATIONAL, \u00E0 compter du 1er janvier 2024. Aucune action n\u0027est \u00E9chang\u00E9e, et les organes d\u0027administration ont approuv\u00E9 ce projet \u00E0 l\u0027unanimit\u00E9 le 18 avril 2024.",
  "co_filed_documents": [
    "Formulaire de d\u00E9p\u00F4t au greffe",
    "Formulaire de publication au Moniteur belge"
  ],
  "detected_real_type": "fusion_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Renaud Dehareng",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Guillaume Taillandier",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "CURIUM INTERNATIONAL"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "representant permanent du commissaire",
      "person": {
        "rrn": null,
        "name": "Xavier Nys",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "representant permanent du commissaire",
      "person": {
        "rrn": null,
        "name": "Micha\u00EBl Focant",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "Curium International"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "representant permanent du commissaire",
      "person": {
        "rrn": null,
        "name": "Xavier Nys",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "representant permanent du commissaire",
      "person": {
        "rrn": null,
        "name": "Dominic Rousselle",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "Curium International"
  }
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "siege_social",
      "new_address": {
        "raw": "BOULEVARD BISCHOFFSHEIM 39. BO\u00CETE 4-1000 BRUXELLES",
        "city": "Bruxelles",
        "region": "brussels_hoofdstedelijk_gewest",
        "street": "boulevard bischoffsheim",
        "country": "BE",
        "postcode": "1000",
        "box_number": "4",
        "street_number": "39",
        "locality_suffix": null
      },
      "old_address": {
        "raw": "avenue de la toison d\u0027or 67 1060 Saint-Gilles",
        "city": "Saint-Gilles",
        "region": "brussels_hoofdstedelijk_gewest",
        "street": "avenue de la toison d\u0027or",
        "country": "BE",
        "postcode": "1060",
        "box_number": null,
        "street_number": "67",
        "locality_suffix": null
      },
      "effective_date": "2021-07-02",
      "evidence_quote": "Le Conseil d\u0027administration d\u00E9cide, \u00E0 l\u0027unanimit\u00E9, de transf\u00E9rer le si\u00E8ge social \u00E0 BOULEVARD BISCHOFFSHEIM 39. BO\u00CETE 4-1000 BRUXELLES.",
      "region_changed": false,
      "is_statute_change": false,
      "nationality_change": false,
      "old_address_source": "act_body",
      "statute_clause_text": null,
      "statute_article_number": null,
      "effective_date_qualifier": "absolute",
      "statutaire_vs_werkelijke": "statutaire",
      "linguistic_region_changed": false,
      "court_jurisdiction_changed": false,
      "effective_date_is_approximate": false
    }
  ],
  "notary": {
    "name": "Mailys Dessain",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": null,
    "filing_date": "2021-07-02",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "raad_van_bestuur",
    "date": "2021-07-02",
    "unanimous": true
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "Curium International",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Mailys Dessain",
    "org_rep_person_name": null,
    "person_role_at_subject": "mandataire sp\u00E9cial"
  },
  "co_filed_documents": [
    "Extrait du proc\u00E8s-verbal du conseil d\u0027administration du 2 juillet 2021"
  ]
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "auditor",
      "person": {
        "rrn": null,
        "name": "KPMG R\u00E9viseurs d\u0027Entreprises BV/SRL",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "auditor representative",
      "person": {
        "rrn": null,
        "name": "Dominic Rousselle",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "Soci\u00E9t\u00E9 anonyme"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "gestion des affaires r\u00E8glementaires (pouvoirs d\u00E9l\u00E9gu\u00E9s)",
      "person": {
        "rrn": null,
        "name": "V\u00EDncent Sarrazin",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "Pharmacien Responsable",
      "person": {
        "rrn": null,
        "name": "Marie d\u0027Arpiany",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "Curium International"
  }
}

{
  "stage": null,
  "notary": {
    "name": "Alexis Wochenmarkt",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2019-09-12",
    "filing_date": "2018-11-14",
    "act_kind_objet": "Correction d\u0027une publication ant\u00E9rieure au Moniteur Belge"
  },
  "decision": {
    "body": "algemene_vergadering",
    "act_date": "2018-11-14",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "other",
  "report_waiver": null,
  "restructuring": {
    "parties": [],
    "exchange_ratio": null,
    "legal_articles": [
      "12:7",
      "12:50"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": null,
    "real_estate_included": false,
    "patrimony_description": null,
    "equity_transferred_eur": null,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "Curium International SA",
    "legal_form": "SA"
  },
  "detected_kind_raw": "material_correction",
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Alexis Wochenmarkt",
    "org_rep_person_name": null
  },
  "summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale du 14 novembre 2018 a nomm\u00E9 KPMG R\u00E9viseurs d\u0027Entreprises SCRL comme commissaire aux comptes pour un mandat de trois ans, dont l\u0027expiration \u00E9tait erron\u00E9ment indiqu\u00E9e \u00E0 l\u0027assembl\u00E9e g\u00E9n\u00E9rale 2021. Cette erreur a \u00E9t\u00E9 corrig\u00E9e par une d\u00E9cision de rectification, confirmant que le mandat expirera \u00E0 l\u0027assembl\u00E9e g\u00E9n\u00E9rale 2021 (comptes 2020). Le commissaire a \u00E9t\u00E9 d\u00E9sign\u00E9 avec son repr\u00E9sentant permanent, Monsieur Dominic Rousselle.",
  "co_filed_documents": [],
  "detected_real_type": "other",
  "referenced_correction": {
    "prior_pub_date": "2018-11-14",
    "what_corrected": "Erreur dans le mandat du commissaire r\u00E9viseur : la dur\u00E9e devait expirer \u00E0 l\u0027assembl\u00E9e g\u00E9n\u00E9rale 2021 (comptes 2020), non 2021 comme indiqu\u00E9 par erreur.",
    "prior_pub_number": "19121851"
  },
  "should_reroute_to_category": null
}

{
  "notary": {
    "name": "Fran\u00E7ois HERINCKX",
    "firm_city": null,
    "firm_name": "Herinckx \u0026 Penne, notaires associ\u00E9s",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2019-04-09",
    "filing_date": "2019-04-05",
    "act_kind_objet": "verbatim"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "date": "2019-03-29",
    "unanimous": true
  },
  "agm_change": {
    "new_schedule": null,
    "old_schedule": null,
    "effective_from_year": 2019,
    "rule_changes_summary": "L\u0027objet social a \u00E9t\u00E9 modifi\u00E9 pour inclure de nouveaux domaines d\u0027activit\u00E9, notamment la recherche et le d\u00E9veloppement dans le domaine de la physique appliqu\u00E9e, la fabrication et la commercialisation de m\u00E9dicaments radiopharmaceutiques, ainsi que des services de conseil strat\u00E9gique, RH et audits. L\u0027objet a \u00E9t\u00E9 \u00E9largi pour couvrir des activit\u00E9s de gestion de ressources humaines, de conseil organisationnel, et de participation \u00E0 des soci\u00E9t\u00E9s li\u00E9es."
  },
  "detected_kind": "agm_rules_change",
  "other_address": null,
  "mandate_renewal": null,
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "Curium International",
    "legal_form": "SA"
  },
  "accounts_deposit": null,
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "exp\u00E9dition",
    "deux procurations",
    "coordination des statuts"
  ],
  "fiscal_year_change": null,
  "liquidation_closure": {
    "liquidator_name": null,
    "discharge_granted": false,
    "deficit_amount_eur": null,
    "deficit_or_surplus": null,
    "liquidator_address": null,
    "surplus_amount_eur": null,
    "court_decision_date": null,
    "books_custodian_name": null,
    "court_approving_plan": null,
    "books_custody_address": null
  },
  "officer_designation": null,
  "special_procuration": {
    "grantee_kbo": null,
    "grantee_name": null,
    "grantor_name": null,
    "scope_summary": null,
    "monetary_cap_eur": null,
    "scope_categories": [],
    "termination_clause": null,
    "substitution_allowed": false
  },
  "is_volet_a_only_stub": true,
  "vakbekwaamheid_change": null,
  "should_reroute_to_category": null,
  "single_shareholder_declaration": null
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "administrateur d\u00E9l\u00E9gu\u00E9",
      "person": {
        "rrn": null,
        "name": "Renaud Dehareng",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "Curium International SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "commissaire",
      "person": {
        "rrn": null,
        "name": "KPMG R\u00E9viseurs d\u0027Entreprises SCRL",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "repr\u00E9sentant permanent du commissaire",
      "person": {
        "rrn": null,
        "name": "Dominic Rouselle",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "Curium International"
  }
}

{
  "events": [
    {
      "kind": "zetel_initial_set",
      "seat_type": "siege_social",
      "new_address": {
        "raw": "Avenue de la Toison d\u0027Or 67, 1060 Saint-Gilles",
        "city": "Saint-Gilles",
        "region": "brussels_hoofdstedelijk_gewest",
        "street": "Avenue de la Toison d\u0027Or",
        "country": "BE",
        "postcode": "1060",
        "box_number": null,
        "street_number": "67",
        "locality_suffix": null
      },
      "old_address": {
        "raw": "Avenue de la Toison d\u0027Or 67, 1000 Bruxelles",
        "city": "Bruxelles",
        "region": "brussels_hoofdstedelijk_gewest",
        "street": "Avenue de la Toison d\u0027Or",
        "country": "BE",
        "postcode": "1000",
        "box_number": null,
        "street_number": "67",
        "locality_suffix": null
      },
      "effective_date": "2018-09-11",
      "evidence_quote": "apr\u00E8s avoir rappel\u00E9 que le conseil d\u2019administration a d\u00E9cid\u00E9 en date du 21 juin 2017 de transf\u00E9rer le si\u00E8ge social \u00E0 1000 Bruxelles, avenue de la Toison d\u0027Or 67 \u2013 d\u00E9cision publi\u00E9e par extrait \u00E0 l\u2019annexe au Moniteur belge du 23 ao\u00FBt 2017 sous le num\u00E9ro 17122062 \u2013, de modifier l\u2019article 2 des statuts ",
      "region_changed": false,
      "is_statute_change": true,
      "nationality_change": false,
      "old_address_source": "header_volledig_adres",
      "statute_clause_text": "le si\u00E8ge social est officiellement fix\u00E9 \u00E0 1060 Saint-Gilles, avenue de la Toison d\u0027Or 67 d\u00E8s lors que le num\u00E9ro 67 de l\u2019avenue de la Toison d\u0027Or est situ\u00E9 sur le territoire de la Commune de Saint-Gilles.",
      "statute_article_number": "2",
      "effective_date_qualifier": "absolute",
      "statutaire_vs_werkelijke": "statutaire",
      "linguistic_region_changed": false,
      "court_jurisdiction_changed": false,
      "effective_date_is_approximate": false
    },
    {
      "kind": "zetel_clause_amendment_no_move",
      "seat_type": "siege_social",
      "new_address": {
        "raw": "Avenue de la Toison d\u0027Or 67, 1060 Saint-Gilles",
        "city": "Saint-Gilles",
        "region": "brussels_hoofdstedelijk_gewest",
        "street": "Avenue de la Toison d\u0027Or",
        "country": "BE",
        "postcode": "1060",
        "box_number": null,
        "street_number": "67",
        "locality_suffix": null
      },
      "old_address": {
        "raw": "Avenue de la Toison d\u0027Or 67, 1000 Bruxelles",
        "city": "Bruxelles",
        "region": "brussels_hoofdstedelijk_gewest",
        "street": "Avenue de la Toison d\u0027Or",
        "country": "BE",
        "postcode": "1000",
        "box_number": null,
        "street_number": "67",
        "locality_suffix": null
      },
      "effective_date": "2018-09-11",
      "evidence_quote": "de changer la d\u00E9nomination de la soci\u00E9t\u00E9 en \u0022Curium International\u0022 et de modifier en cons\u00E9quence l\u2019article 1 des statuts.",
      "region_changed": false,
      "is_statute_change": true,
      "nationality_change": false,
      "old_address_source": "header_volledig_adres",
      "statute_clause_text": "de changer la d\u00E9nomination de la soci\u00E9t\u00E9 en \u0022Curium International\u0022 et de modifier en cons\u00E9quence l\u2019article 1 des statuts.",
      "statute_article_number": "1",
      "effective_date_qualifier": "absolute",
      "statutaire_vs_werkelijke": "statutaire",
      "linguistic_region_changed": false,
      "court_jurisdiction_changed": false,
      "effective_date_is_approximate": false
    }
  ],
  "notary": {
    "name": "Fran\u00E7ois HERINCKX",
    "firm_city": null,
    "firm_name": "Herinckx \u0026 Penne, notaires associ\u00E9s",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2018-09-17",
    "filing_date": "2018-09-13",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "algemene_vergadering",
    "date": "2018-09-11",
    "unanimous": true
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA Pharma",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Fran\u00E7ois HERINCKX",
    "org_rep_person_name": null,
    "person_role_at_subject": "notaire associ\u00E9"
  },
  "co_filed_documents": [
    "exp\u00E9dition",
    "procurations",
    "coordination des statuts"
  ]
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Timothy Colson",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Xavier Defourt",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA PHARMA"
  }
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "siege_social",
      "new_address": {
        "raw": "1000 Bruxelles, Avenue de la Toison d\u0027Or 67",
        "city": "Bruxelles",
        "region": "brussels_hoofdstedelijk_gewest",
        "street": "Avenue de la Toison d\u0027Or",
        "country": "BE",
        "postcode": "1000",
        "box_number": null,
        "street_number": "67",
        "locality_suffix": null
      },
      "old_address": {
        "raw": "Chemin du Cyclotron 3, 1348 Louvain-La-Neuve",
        "city": "Louvain-La-Neuve",
        "region": "waals_gewest",
        "street": "Chemin du Cyclotron",
        "country": "BE",
        "postcode": "1348",
        "box_number": null,
        "street_number": "3",
        "locality_suffix": null
      },
      "effective_date": "2017-06-21",
      "evidence_quote": "Le Conseil d\u0027administration d\u00E9cide, \u00E0 l\u0027unanimit\u00E9, de transf\u00E9rer le si\u00E8ge social \u00E0 1000 Bruxelles, Avenue de la Toison d\u0027Or 67.",
      "region_changed": true,
      "is_statute_change": false,
      "nationality_change": false,
      "old_address_source": "header_volledig_adres",
      "statute_clause_text": null,
      "statute_article_number": null,
      "effective_date_qualifier": "absolute",
      "statutaire_vs_werkelijke": "statutaire",
      "linguistic_region_changed": false,
      "court_jurisdiction_changed": true,
      "effective_date_is_approximate": false
    }
  ],
  "notary": {
    "name": "Alexis Wochenmarkt",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2017-08-23",
    "filing_date": "2017-08-11",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "raad_van_bestuur",
    "date": "2017-06-21",
    "unanimous": true
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA PHARMA",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Alexis Wochenmarkt",
    "org_rep_person_name": null,
    "person_role_at_subject": "Mandataire sp\u00E9cial"
  },
  "co_filed_documents": [
    "Extrait du proc\u00E8s-verbal du Conseil d\u0027administration du 21 juin 2017"
  ]
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "administrator",
      "person": {
        "rrn": null,
        "name": "Renaud DEHARENG",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "president of the board",
      "person": {
        "rrn": null,
        "name": "Renaud DEHARENG",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrator-delegate",
      "person": {
        "rrn": null,
        "name": "Renaud DEHARENG",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrator",
      "person": {
        "rrn": null,
        "name": "Timothy COLSON",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA Pharma"
  }
}

{
  "events": [
    {
      "kind": "capital_decrease",
      "after_eur": 20000000.0,
      "delta_eur": -98258148.56,
      "before_eur": 118258148.56,
      "contribution_type": null
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA Pharma"
  }
}

{
  "stage": "completed",
  "notary": {
    "name": "Fran\u00E7ois HERINCKX",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": null,
    "filing_date": "2016-10-03",
    "act_kind_objet": "FUSION PAR ABSORPTION - TRANSFERT UNIVERSEL DE PATRIMOINE"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2016-09-16",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0860.215.596",
        "name": "IBA Pharma",
        "role": "acquiring",
        "address": "1348 Ottignies - Louvain-la-Neuve (Louvain-la-Neuve), Chemin du Cyclotron 3",
        "is_foreign": false,
        "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0879.656.475",
        "name": "RADIOPHARMA PARTNERS",
        "role": "absorbed",
        "address": "6220 Fleurus, Zoning Industriel, avenue de l\u0027Esp\u00E9rance 1",
        "is_foreign": false,
        "legal_form": "soci\u00E9t\u00E9 anonyme",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "676, 1\u00B0",
      "74"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2016-09-15",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "L\u0027int\u00E9gralit\u00E9 du patrimoine actif et passif de la soci\u00E9t\u00E9 anonyme RADIOPHARMA PARTNERS est transf\u00E9r\u00E9e \u00E0 IBA Pharma \u00E0 la date du 15 septembre 2016 \u00E0 minuit, par transfert universel de patrimoine.",
    "equity_transferred_eur": null,
    "accounting_effective_date": "2016-09-15"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA Pharma",
    "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Fran\u00E7ois HERINCKX",
    "org_rep_person_name": null
  },
  "summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire des associ\u00E9s de IBA Pharma a approuv\u00E9 la fusion par absorption de la soci\u00E9t\u00E9 anonyme RADIOPHARMA PARTNERS, dont la dissolution sans liquidation a \u00E9t\u00E9 d\u00E9cid\u00E9e en amont. Le transfert universel du patrimoine actif et passif de RADIOPHARMA PARTNERS \u00E0 IBA Pharma a eu lieu le 15 septembre 2016 \u00E0 minuit, conform\u00E9ment \u00E0 l\u0027article 676, 1\u00B0, du Code des soci\u00E9t\u00E9s. Le projet de fusion avait \u00E9t\u00E9 publi\u00E9 \u00E0 l\u0027annexe du Moniteur belge le 12 ao\u00FBt 2016 sous le num\u00E9ro 16114748.",
  "co_filed_documents": [
    "une exp\u00E9dition",
    "une procuration"
  ],
  "detected_real_type": "fusion_completed",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "stage": "completed",
  "notary": {
    "name": "Fran\u00E7ois HERINCKX",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": null,
    "filing_date": "2016-08-18",
    "act_kind_objet": ""
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2016-07-29",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0860.215.596",
        "name": "IBA Pharma",
        "role": "acquiring",
        "address": "Chemins du Cyclotron 3, 1348 Ottignies - Louvain-la-Neuve, Belgique",
        "is_foreign": false,
        "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0819.674.051",
        "name": "Molecular Imaging",
        "role": "absorbed",
        "address": "Chemins du Cyclotron 3, 1348 Ottignies - Louvain-la-Neuve, Belgique",
        "is_foreign": false,
        "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "676, 1\u00B0",
      "74"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2015-12-31",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": true,
    "patrimony_description": "L\u0027int\u00E9gralit\u00E9 du patrimoine actif et passif de la soci\u00E9t\u00E9 \u0027Molecular Imaging\u0027 est transf\u00E9r\u00E9e \u00E0 \u0027IBA Pharma\u0027. Le transfert porte sur l\u0027ensemble du patrimoine, y compris les biens immobiliers et les droits et obligations.",
    "equity_transferred_eur": null,
    "accounting_effective_date": "2015-12-31"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA Pharma",
    "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Fran\u00E7ois HERINCKX",
    "org_rep_person_name": null
  },
  "summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire des associ\u00E9s de \u0027IBA Pharma\u0027 a approuv\u00E9 la fusion par absorption de \u0027Molecular Imaging\u0027, soci\u00E9t\u00E9 absorb\u00E9e, par transfert universel de patrimoine. Cette fusion, pr\u00E9alablement publi\u00E9e au Moniteur belge le 28 juin 2016 sous le num\u00E9ro 16088392, a pour effet de transf\u00E9rer l\u0027int\u00E9gralit\u00E9 du patrimoine actif et passif de \u0027Molecular Imaging\u0027 \u00E0 \u0027IBA Pharma\u0027 \u00E0 compter du 31 d\u00E9cembre 2015.",
  "co_filed_documents": [
    "une exp\u00E9dition",
    "une procuration"
  ],
  "detected_real_type": "fusion_completed",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Renaud Dehareng",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA PHARMA"
  }
}

{
  "stage": "proposal",
  "notary": {
    "name": "Fran\u00E7ois HERINCKX",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2016-08-12",
    "filing_date": "2016-06-29",
    "act_kind_objet": ""
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2016-06-29",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": {
    "summary": "Les actionnaires des soci\u00E9t\u00E9s IBA PHARMA et RADIOPHARMA PARTNERS ont renonc\u00E9 \u00E0 l\u0027\u00E9tablissement d\u0027un \u00E9tat comptable arr\u00EAt\u00E9 dans les trois mois pr\u00E9c\u00E9dant la date du projet de fusion.",
    "articles": [
      "720 \u00A72"
    ]
  },
  "restructuring": {
    "parties": [
      {
        "kbo": "0860.215.596",
        "name": "IBA PHARMA",
        "role": "acquiring",
        "address": "Chemin du Cyclotron 3, 1348 Louvain-la-Neuve",
        "is_foreign": false,
        "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": null
      },
      {
        "kbo": "0879.656.475",
        "name": "RADIOPHARMA PARTNERS",
        "role": "absorbed",
        "address": "Avenue de l\u0027Esp\u00E9rance (F)1, 6220 Fleurus",
        "is_foreign": false,
        "legal_form": "soci\u00E9t\u00E9 anonyme",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "676",
      "719",
      "724",
      "726"
    ],
    "is_cross_border": false,
    "is_silent_merger": true,
    "balance_basis_date": "2016-09-16",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "L\u0027int\u00E9gralit\u00E9 du patrimoine de RADIOPHARMA PARTNERS, activement et passivement, est transf\u00E9r\u00E9e \u00E0 IBA PHARMA, y compris les actifs, passifs exigibles et engagements contract\u00E9s. Les actions et parts b\u00E9n\u00E9ficiaires de RADIOPHARMA PARTNERS sont annul\u00E9es.",
    "equity_transferred_eur": 61500.0,
    "accounting_effective_date": "2016-09-16"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA PHARMA",
    "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Ma\u00EElys Dessain",
    "org_rep_person_name": null
  },
  "summary_narrative": "Le 29 juin 2016, les organes de gestion d\u0027IBA PHARMA (soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e) et de RADIOPHARMA PARTNERS (soci\u00E9t\u00E9 anonyme) ont d\u00E9cid\u00E9 de soumettre un projet de fusion par absorption \u00E0 leurs assembl\u00E9es g\u00E9n\u00E9rales. IBA PHARMA absorbera RADIOPHARMA PARTNERS sans liquidation, en transf\u00E9rant l\u0027int\u00E9gralit\u00E9 de son patrimoine. Cette fusion est silencieuse, car IBA PHARMA d\u00E9tenait d\u00E9j\u00E0 toutes les actions et parts b\u00E9n\u00E9ficiaires de RADIOPHARMA PARTNERS. L\u0027effet comptable est r\u00E9troactif au 16 septembre 2016. Les rapports comptables ont \u00E9t\u00E9 dispens\u00E9s conform\u00E9ment \u00E0 l\u0027article 720 \u00A72 du Code ",
  "co_filed_documents": [],
  "detected_real_type": "fusion_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "stage": "proposal",
  "notary": {
    "name": "Fran\u00E7ois HERINCKX",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2016-06-28",
    "filing_date": "2016-06-16",
    "act_kind_objet": ""
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2016-06-16",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0860.215.596",
        "name": "IBA PHARMA",
        "role": "acquiring",
        "address": "Chemin du Cyclotron 3 1348 Louvain-la-Neuve",
        "is_foreign": false,
        "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": null,
        "name": "MOLECULAR IMAGING",
        "role": "absorbed",
        "address": "Chemin du cyclotron 3, Ottignies Louvain-la-Neuve, 1348",
        "is_foreign": false,
        "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "676",
      "719",
      "724",
      "726"
    ],
    "is_cross_border": false,
    "is_silent_merger": true,
    "balance_basis_date": "2015-12-31",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "L\u0027int\u00E9gralit\u00E9 du patrimoine, actif et passif, de MOLECULAR IMAGING est transf\u00E9r\u00E9e \u00E0 IBA PHARMA. Cela inclut les immobilisations incorporelles, corporelles, financi\u00E8res, les cr\u00E9ances, les stocks, les dettes et les capitaux propres.",
    "equity_transferred_eur": 16129527.67,
    "accounting_effective_date": "2016-01-01"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA PHARMA",
    "legal_form": "soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Alexis Wochenmarkt",
    "org_rep_person_name": null
  },
  "summary_narrative": "Le 16 juin 2016, les organes de gestion d\u0027IBA PHARMA et de MOLECULAR IMAGING ont d\u00E9cid\u00E9 de soumettre \u00E0 leurs assembl\u00E9es g\u00E9n\u00E9rales des associ\u00E9s un projet de fusion par absorption, conform\u00E9ment aux articles 676 et 719 du Code des soci\u00E9t\u00E9s. IBA PHARMA absorbera MOLECULAR IMAGING sans liquidation, en transf\u00E9rant l\u0027int\u00E9gralit\u00E9 de son patrimoine. Cette fusion est silencieuse, car IBA PHARMA d\u00E9tient d\u00E9j\u00E0 toutes les parts de la soci\u00E9t\u00E9 absorb\u00E9e. L\u0027effet comptable est r\u00E9troactif au 1er janvier 2016.",
  "co_filed_documents": [],
  "detected_real_type": "fusion_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "g\u00E9rant",
      "person": {
        "rrn": null,
        "name": "Jamshid Keynejad",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "g\u00E9rant",
      "person": {
        "rrn": null,
        "name": "Aaron Davenport",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA PHARMA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "auditor",
      "person": {
        "rrn": null,
        "name": "KPMG R\u00E9viseur d\u0027entreprise, SCCRL",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA PHARMA"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA Pharma"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA Pharma"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0860.215.596",
    "name_full": "IBA Pharma"
  }
}